



# Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis

Afisi S. Ismaila · Katrin Haeussler · Alexandrosz Czira ·  
Vanita Tongbram · Mia Malmenäs · Jatin Agarwal · Maria Nassim ·  
Marija Živković-Gojović · Yunrong Shen · Xinzhe Dong ·  
Maria Duarte · Chris Compton · Claus F. Vogelmeier ·  
David M. G. Halpin

Published online: September 2, 2022  
© Springer Healthcare Ltd., part of Springer Nature 2022

Correction to: Adv Ther  
<https://doi.org/10.1007/s12325-022-02234-x>

The authors regret to inform readers that the labels for the ‘treatment favour’ arrows were

incorrectly labelled in Fig. 4. The ‘Favours UMEC/VI 62.5/25’ and ‘Favours comparator’ labels were appended to the wrong arrows and the corrected Fig. 4 is shown below. Please note that the data have not changed between versions.

---

The original article can be found online at <https://doi.org/10.1007/s12325-022-02234-x>.

---

A. S. Ismaila  
R&D Global Medical, GSK, Collegeville, PA, USA

A. S. Ismaila  
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada

K. Haeussler · M. Nassim  
ICON Plc, München, Germany

A. Czira · M. Duarte · C. Compton  
R&D Global Medical, GSK, Brentford, Middlesex, UK

V. Tongbram  
ICON Plc, North Wales, PA, USA

M. Malmenäs  
ICON Plc, Stockholm, Sweden

J. Agarwal  
ICON Plc, Bengaluru, Karnataka, India

M. Živković-Gojović  
ICON Plc, Burlington, ON, Canada


Y. Shen  
ICON Plc, Cambridge, MA, USA

X. Dong  
ICON Plc, Vancouver, BC, Canada

C. F. Vogelmeier  
Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany

D. M. G. Halpin  
University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK

A. S. Ismaila (✉)  
Value Evidence and Outcomes, GSK, 1250 South Collegeville Road, Collegeville, PA 19426-0989, USA  
e-mail: [afisi.s.ismaila@gsk.com](mailto:afisi.s.ismaila@gsk.com)



**Fig. 4** Fixed effects model of mean difference in change from baseline in TDI focal score of UMEC/VI versus **a** dual therapy and **b** monotherapy at 24 weeks. Assessment of heterogeneity/inconsistency:  $I^2 = 0\%$ ;  $Q = 12.60$ ;  $p = 0.4793$ . *ACL* aclidinium, *CFB* change from baseline,

*CI* confidence interval, *FOR* formoterol fumarate, *FP* fluticasone propionate, *GLY* glycopyrronium, *IND* indacaterol, *PBO* placebo, *SAL* salmeterol, *TDI* Transitional Dyspnoea Index, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol

**Open Access.** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are

included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.